SGK Inhibitors

Serum and glucocorticoid-regulated kinase (SGK) is a serine/threonine kinase belonging to the AGC (PKA/PKG/PKC) family, playing a crucial role in regulating ion transport, cell survival, and proliferation. SGK isoforms (SGK1, SGK2, SGK3) are activated by various stimuli, including growth factors, hormones (like aldosterone and glucocorticoids), and osmotic stress, often through phosphorylation by upstream kinases such as PDK1. The main signaling pathway involves SGK phosphorylating a range of downstream targets, including ion channels (e.g., ENaC, Na+/K+-ATPase), transporters, and transcription factors, thereby modulating their activity and cellular localization. This regulation is critical for maintaining electrolyte balance, cellular volume, and promoting cell survival pathways like PI3K/Akt signaling. SGK is implicated in a variety of physiological processes and diseases. Its role in regulating sodium and potassium transport makes it important in cardiovascular homeostasis and blood pressure regulation.

Overexpression or hyperactivity of SGK has been linked to hypertension, cardiac hypertrophy, and kidney diseases. In cancer, SGK can promote tumor cell survival, proliferation, and resistance to apoptosis and chemotherapy, making it an attractive target for anticancer therapies. It is also involved in neurological functions and has been implicated in conditions like epilepsy and neuropathic pain. Inhibitors targeting SGK are being developed as potential therapeutic agents for these conditions. Current research is primarily in the preclinical and early clinical stages. Several small molecule inhibitors have been identified, demonstrating efficacy in preclinical models of cancer, hypertension, and other SGK-dependent diseases.

Notable examples include compounds like GSK2118334 and other ATP-competitive inhibitors. Inhibitors can be classified based on their selectivity for different SGK isoforms (SGK1, SGK2, SGK3) or their mechanism of action, such as ATP-competitive inhibitors that block the kinase active site or allosteric inhibitors. Achieving isoform selectivity is a challenge, as SGK isoforms share significant structural homology with other AGC kinases. Potential toxicity, particularly related to electrolyte imbalance and effects on normal cell survival, is a major concern. Strategies to overcome resistance and improve therapeutic outcomes include combination therapies with existing treatments, such as chemotherapy or antihypertensive drugs. Research tools, including isoform-specific siRNAs and small molecule inhibitors, are essential for dissecting SGK signaling pathways and validating its role as a drug target.